Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Cibisatamab (Primary) ; Ciforadenant (Primary) ; Cobimetinib (Primary) ; Docetaxel (Primary) ; Evolocumab (Primary) ; Gemcitabine (Primary) ; Ipatasertib (Primary) ; Linagliptin (Primary) ; Pemetrexed (Primary) ; Sacituzumab govitecan (Primary) ; Tocilizumab
Indications Carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms MORPHEUS; Morpheus Lung; MORPHEUS-NSCLC
Sponsors Genentech; Roche

31 May 2024 Planned End Date changed from 30 Sep 2027 to 30 Nov 2026.
31 May 2024 Planned primary completion date changed from 30 Jun 2026 to 30 Sep 2025.
31 May 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com